Àá½Ã¸¸ ±â´Ù·Á ÁÖ¼¼¿ä. ·ÎµùÁßÀÔ´Ï´Ù.

À§¾Ï, ´ëÀå¾Ï ¹× °£¾Ï ¼¼Æ÷ÁÖ¿¡¼­ p16INK4A ´Ü¹é ¹ßÇö The p161NK4A Expression in Stomach Cancer, Colon Cancer and Hematoma Cell Lines

´ëÇѾÏÇÐȸÁö 1998³â 30±Ç 3È£ p.527 ~ 535
¼Ò¼Ó »ó¼¼Á¤º¸
ÃÖ¼±ÁÖ/Sun Ju Choi ±è¼ö±â/±è¼¼Á¾/°íÃá¸í/¹ÚÀ±¼±/ÃÖ¼±ÁÖ/±è¼ö±â/°íÃá¸í/Soo Kie Kim/Se Jong Kim/Choon Myung Koh/Yoon-Sun Park/Sun Ju Choi/Soo Kie Kim/Choon Myung Koh

Abstract

¼­·Ð
¸ðµç ¾ÏÀÇ ¹ß»ý °úÁ¤¿¡¼­ ¼¼Æ÷ ¼ºÀå Á¶Àý ±âÀüÀÇ º¯È­´Â ÇʼöÀûÀÌ¸ç ½ÇÁ¦·Î ¸î¸îÀÇ ¼¼Æ÷
ÁÖ±â Á¶Àý À¯ÀüÀÚ´Â ¾ÏÀ¯ÀüÀÚ(oncogene) ¶Ç´Â Á¾¾ç ¾ïÁ¦ À¯ÀüÀÚ(tumor suppressor gene)·Î
¼­ ¿ªÇÒÀ» Á÷Á¢ ¼öÇàÇÑ´Ù. ÀÌ·± »ç½ÇÀº ¼¼Æ÷ ÁÖ±â Á¶Àý ÀÎÀÚ°¡ ¾Ï ¹ß»ý °úÁ¤°ú ¹ÐÁ¢ÇÑ °ü°è
°¡ ÀÖÀ½À» ½Ã»çÇÏ°í ÀÖ´Ù. Á¾¾ç¹ß»ý¿¡ ±â¿©ÇÒ °ÍÀ¸·Î ÃßÁ¤µÇ´Â ¼¼Æ÷ÁÖ±âÁ¶ÀýÀÎÀڷδ ¼¼Æ÷
ÁÖ±âÁøÇàÀ» À¯µµÇÏ´Â cdk4, cyclinD¿Í ¼¼Æ÷ÁÖ±âÀÇ ÁøÇàÀ» ¾ïÁ¦ÇÏ´Â p53, p2l, pRB,
p161NK4A µîÀÌ ´ëÇ¥ÀûÀÌ´Ù. ÀÌ Áß¿¡¼­ p161NK4A´Â 9p21¿¡
Á¸ÀçÇÏ´Â À¯ÀüÀڷμ­ cdk4 inhibitorÀÎ p161NK4AÀ» encodingÇÏ°í Àִµ¥ ÃÖ
±Ù ¸î ³â°£ ºñ ¼Ò¼¼Æ÷¼º Æó¾Ï, ½Å°æ±³Á¾, ¹éÇ÷º´, ¹æ±¤¾ÏÀ» ºñ·ÔÇÑ ¿©·¯ Á¾·ùÀÇ ¾Ï¼¼Æ÷¿¡¼­
°á¼ÕÀÌ ÀϾ´Â °æ¿ì°¡ ¸¹´Ù°í º¸°íµÇ°í ÀÖ´Ù. p161NK4A À¯ÀüÀÚ°¡ °á¼ÕµÈ
°æ¿ì »ó´ëÀûÀ¸·Î cyclinD-cdk4 º¹ÇÕü Çü¼ºÀÌ Áõ°¡ÇÏ¿© pRE ±â´ÉÀÇ ¼Õ½ÇÀ» ÃÊ·¡ÇÏ°Ô µÈ´Ù.
p161NK4AÀ¯ÀüÀÚÀÇ °á¼ÕÀº ¼¼Æ÷ Á¾·ù¿¡ µû¶ó ´Ù¸£°Ô ³ªÅ¸³ª ¼º»ó¼¼Æ÷Á¾, ½Å
°æ±³Á¾, Èæ»öÁ¾, À¯¹æ¾Ï, ¹éÇ÷º´¿¡¼­´Â 60¡­80%ÀÇ ³ôÀº °á¼ÕÀ²À» º¸ÀÎ ¹Ý¸é¿¡ ´ëÀå¾ÏÀ̳ª
½Å°æ¾Æ¼¼Æ÷Á¾¿¡¼­´Â 10%ÀÌÇÏÀÇ ³·Àº °á¼ÕÀ²ÀÌ º¸°íµÇ¾ú´Ù. ¶ÇÇÑ ÀϺΠ¾Ï ¼¼Æ÷ÁÖ¿¡¼­´Â À¯
ÀüÀÚ °á¼ÕÀÌ ¾øÀ½¿¡µµ ºÒ±¸ÇÏ°í p161NK4A mRNA³ª
p161NK4A ´Ü¹éÀÇ ¹ßÇöÀÌ ÀϾÁö ¾Ê´Â °ÍÀÌ º¸°íµÇ¾ú´Ù. ±×¸®°í
p161NK4AÀ¯ÀüÀÚ°¡ °á¼ÕµÇ¾î ÀÖ´Â ¼¼Æ÷¿¡ ÀÌ À¯ÀüÀÚ¸¦ »ðÀÔÇØ ÁØ °æ¿ì¿¡ ¼¼
Æ÷ÀÇ ¼ºÀåÀÌ Á¤ÁöµÈ´Ù´Â º¸°í°¡ ÀÖ¾î ¾ÏÀÇ Ä¡·á¿¡ ÀÌ¿ëÇÒ °¡´É¼ºµµ Á¦½ÃµÇ°í ÀÖ´Ù.
ÇöÀç p161NK4A ´Ü¹é ¹ßÇö °úÁ¤¿¡ °üÇÑ ¸¹Àº ¿¬±¸´Â
p161NK4A À¯ÀüÀÚ °á¼ÕÀÌ ºñ±³Àû ¸¹Àº ¼º»ó¼¼Æ÷Á¾, Èæ»öÁ¾, ºñ ¼Ò¼¼Æ÷¼º Æó¾Ï
µîÀ» ´ë»óÀ¸·Î ÇÏ°í ÀÖ´Ù. ±×·¯³ª ¼­±¸¿¡¼­ ¹ß»ý ºóµµ°¡ ³ôÁö ¾ÊÀº À§¾Ï, °£¾Ï µî¿¡ ´ëÇؼ­
´Â p161NK4AÀ¯ÀüÀÚ °á¼Õ¿¡ ´ëÇÑ ¿¬±¸°¡ ¸¹Áö ¾ÊÀ¸¸ç, ´ëÀå¾Ï¼¼Æ÷¿¡¼­´Â
p161NK4A À¯ÀüÀÚ °á¼ÕÀº ¾ø°í ´Ü¹é ¹ßÇöÀÇ ÀÌ»óÀÌ ÀÖ´Ù´Â °Í¸¸ º¸°íµÈ ¹Ù
ÀÖ´Ù. Áï p161NK4A °á¼ÕÀÌ ÀûÀº ÀϺΠ¾ÏÁ¾°ú ¿ì¸®³ª¶ó¿¡¼­ ¹ß»ý ºóµµ°¡ ³ô
Àº ¾ÏÀ» ´ë»óÀ¸·Î ÇÑ p161NK4A À¯ÀüÀÚ ¹× ±× ´Ü¹é ¹ßÇö¿¡ ´ëÇÑ ¿¬±¸´Â ¹ÌÁø
ÇÑ ½ÇÁ¤À̸ç ƯÈ÷ ¿ì¸®³ª¶ó ȯÀڷκÎÅÍ ¼ö¸³µÈ ¼¼Æ÷ÁÖ¸¦ ´ë»óÀ¸·Î ÇÑ ¿¬±¸ °á°ú´Â ¾ÆÁ÷ ¹Ì
¹ÌÇÏ´Ù.
ÀÌ¿¡ º» ¿¬±¸¿¡¼­´Â ¿ì¸®³ª¶ó ȯÀڷκÎÅÍ ¼ö¸³µÈ ¼¼Æ÷ÁÖ Áß¿¡¼­ À§¾Ï, ´ëÀå¾Ï ±×¸®°í °£
¾Ï ¼¼Æ÷ÁÖ¸¦ ´ë»óÀ¸·Î p161NK4A À¯ÀüÀÚ °á¼Õ ¿©ºÎ¿Í
p161NK4A ´Ü¹é ¹ßÇöÀ» Á¶»çÇÔÀ¸·Î½á »ó±â ¾ÏÁ¾ ¹ß»ý °úÁ¤¿¡¼­
p161NK4AÀÇ °ü·Ã¼ºÀ» ¾Ë¾Æº¸°íÀÚ ÇÏ¿´´Ù.

Purpose : The p161NK4A gene encodes a specific inhibitor of cell cycle
progression. In recent years, genetic deletion and altered expression of
p161NK4A gene were frequently showed in many human cancers. So, the
p161NK4A gene is considered as tumor suppressor gene. However, there
has been a few data for the p161NK4A in gastric cancer, colon cancer,
and hematoma. So, we investigated the genetic deletion and altered expression of
p161NK4A in gastric cancer, colon cancer and hepatoma cell lines.
Materials and methods : The homozygous deletion of p161NK4A was
examined by using PCR and the protein expression of p161NK4A by using
Western blotting in cancer cell lines established from Korean patients: stomach cancer,
colon cancer and hepatoma cell lines.
Results : Homozygous deletion of p161NK4A was detected only 1
stomach cancer cell line out of 13 cell lines examined. The p161NK4A was
detected in 3 of 13 cancer cell line. These results showed the low frequency of
p161NK4A homozygous deletion and high frequency of
p161NK4A expression alteration in stomach cancer, colon cancer and
hepatoma cell lines.
Conclusion : In this study, it may be suggested that the altered
p161NK4A expression as well as p161NK4A gene deletion
play important role in oncogenesis. Further studies to determine the mechanism of
p161NK4A gene inactivation are expected.

Å°¿öµå

Cancer cell line; p161NK4A homozygous deletion; p161NK4A expression;

¿ø¹® ¹× ¸µÅ©¾Æ¿ô Á¤º¸

 

µîÀçÀú³Î Á¤º¸

KoreaMed
KAMS